Skip to main content
رجوع
Watch Compare

Arcturus Therapeutics Holdings Inc.

جودة البيانات: 100%
ARCT
Nasdaq Manufacturing Chemicals
KWD 8.28
▼ KWD 0.22 (-2.59%)
القيمة السوقية: 235.34 M
السعر
KWD 8.28
القيمة السوقية
235.34 M
نطاق اليوم
KWD 8.20 — KWD 8.46
نطاق 52 أسبوعًا
KWD 5.85 — KWD 24.17
حجم التداول
220,819
فتح KWD 8.46
متوسط 50 يوم / 200 يوم
KWD 7.40
11.93% above
متوسط 50 يوم / 200 يوم
KWD 11.47
27.80% below

Quick Summary

النقاط الرئيسية

Revenue grew 60.51% annually over 5 years — strong growth
Negative free cash flow of -74.50 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 106.65%
Capital efficient — spends only 0.28% of revenue on capex

النمو

Revenue Growth (5Y)
60.51%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)-46.14%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-28.88%
أعلى من متوسط القطاع (-53.41%)
ROIC-23.47%
Net Margin-80.19%
Op. Margin-92.96%

الأمان

Debt / Equity
N/A
Current Ratio7.86
Interest CoverageN/A

التقييم

PE (TTM)
-3.58
أقل من متوسط القطاع (-1.48)
P/B Ratio1.05
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -3.6 -1.5
P/B 1.1 1.6
ROE % -28.9 -53.4
Net Margin % -80.2 -41.5
Rev Growth 5Y % 60.5 1.8
D/E — 0.3

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0.78% weight
NXTE logo NXTE AXS Green Alpha ETF
0.23% weight
GDSTX GDSTX
0.17% weight
GCSAX GCSAX
0.17% weight
GCSCX GCSCX
0.17% weight
GDSRX GDSRX
0.17% weight
GCSSX GCSSX
0.17% weight
GCSIX GCSIX
0.17% weight
GCSUX GCSUX
0.17% weight
GMAPX GMAPX
0.17% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -46.14% Revenue Growth (3Y) -29.87%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 60.51% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 82.03 M Net Income (TTM) -65.78 M
ROE -28.88% ROA -22.24%
Gross Margin N/A Operating Margin -92.96%
Net Margin -80.19% Free Cash Flow (TTM) -74.50 M
ROIC -23.47% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 7.86
Interest Coverage N/A Asset Turnover 0.28
Working Capital 217.50 M Tangible Book Value 224.56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.58 Forward P/E N/A
P/B Ratio 1.05 P/S Ratio 2.87
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -31.66%
Market Cap 235.34 M Enterprise Value 54.98 M
Per Share
EPS (Diluted TTM) -2.40 Revenue / Share 2.89
FCF / Share -2.62 OCF / Share -2.61
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.28% FCF Conversion 113.25%
SBC-Adj. FCF -102.59 M Growth Momentum -106.65

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 82.03 M 152.31 M 166.80 M 206.00 M 12.36 M
Net Income -65.78 M -80.94 M -29.73 M 9.35 M -203.67 M
EPS (Diluted) -2.40 -3.00 -1.12 0.35 —
Gross Profit — — — — —
Operating Income -76.26 M -95.67 M -78.21 M 12.18 M -202.85 M
EBITDA — — — — —
R&D Expenses 112.21 M 195.16 M 192.13 M 147.75 M 173.76 M
SG&A Expenses — — — — —
D&A 3.03 M 3.54 M 2.96 M 1.53 M 1.19 M
Interest Expense — — — — —
Income Tax -4,000.0 -4,000.0 1.84 M 1.30 M —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 271.15 M 344.07 M 429.40 M 450.39 M 392.81 M
Total Liabilities 57.16 M 103.09 M 150.89 M 180.08 M 164.60 M
Shareholders' Equity 213.99 M 240.98 M 278.51 M 270.31 M 228.21 M
Total Debt — — — 40.63 M 15.30 M
Cash & Equivalents 230.91 M 237.03 M 292.01 M 391.88 M 370.49 M
Current Assets 241.45 M 305.98 M 386.59 M 403.33 M 378.96 M
Current Liabilities 36.38 M 65.49 M 81.99 M 126.98 M 99.54 M